Neoadjuvant atezolizumab plus bevacizumab prior liver transplantation for hepatocellular carcinoma
Studies on the combination of atezolizumab and bevacizumab in the neoadjuvant setting prior to liver transplantation for hepatocellular carcinoma have been limited, despite its potential to enhance anti-tumor responses and downstaging, owing to concerns about its safety profile. Among 17 patients who underwent successful liver transplantation following neoadjuvant atezolizumab/bevacizumab, 82% achieved downstaging to within Milan criteria, 94% radiological objective response and 88% pathology response, without drop-outs due to treatment-related adverse events or graft loss. The neoadjuvant combination of atezolizumab plus bevacizumab prior to liver transplantation for hepatocellular carcinoma shows an encouraging safety profile and stands out as a promising pre-transplant optimization treatment, leading to improved oncological outcomes.
Authors
- Parissa Tabrizian (ORCID: https://orcid.org/0000-0002-7881-7497)
- Salvatore Gruttadauria (ORCID: https://orcid.org/0000-0002-9684-8035)
- Vanessa Banz (ORCID: https://orcid.org/0000-0002-4887-5776)
- Josep Maria Llovet (ORCID: https://orcid.org/0000-0003-0547-2667)
- Sherrie Bhoori (ORCID: https://orcid.org/0000-0002-2837-6398)
- Vincenzo Mazzaferro (ORCID: https://orcid.org/0000-0002-4013-8085)
- Neil J. Mehta (ORCID: https://orcid.org/0000-0002-9476-468X)
- Nicolò Simonotti
- Massimo Alberto Iavarone (ORCID: https://orcid.org/0000-0003-3493-6504)
- Rebecca Marino (ORCID: https://orcid.org/0000-0002-2069-6485)
- Marcus Zeitlhoefler
- Francis Y. Yao (ORCID: https://orcid.org/0000-0003-0623-0715)
- Chiara Mazzarelli (ORCID: https://orcid.org/0000-0003-3803-4778)
Institutions
- University of Bern (CH)
- Institució Catalana de Recerca i Estudis Avançats (ES)
- University of California, San Francisco (US)
- University of Milan (IT)
- University Hospital of Bern (CH)
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (IT)
- Ospedale Maggiore (IT)
- Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda (IT)
- Surgical Specialties (United States) (US)
- Fondazione IRCCS Istituto Nazionale dei Tumori (IT)
- Consorci Institut D'Investigacions Biomediques August Pi I Sunyer (ES)
- Icahn School of Medicine at Mount Sinai (US)
Publication Details
- Journal
- JHEP Reports
- Published
- 2024-10-18
- DOI
- https://doi.org/10.1016/j.jhepr.2024.101246
- Citations
- 16
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 5.91
Funders
- Cancer Research UK
- European Commission
- Deutsche Forschungsgemeinschaft
- Fundación Científica Asociación Española Contra el Cáncer
- Generalitat de Catalunya
- Ministerio de Ciencia e Innovación
- Associazione Italiana per la Ricerca sul Cancro
- National Institutes of Health
- HORIZON EUROPE Framework Programme
- Agència de Gestió d'Ajuts Universitaris i de Recerca